Our Journey

The SMT journey has been a pledge, a pledge to save millions. With people in over 69 countries benefitting from our minimally invasive coronary intervention devices, we have truly created a journey that has made a difference. We move ahead with the outlook to cover complete cardiovascular treatment support, each day.

2023
 
SMT strengthens further, Kotak Mahindra buys a stake in SMT
2022
SMT diversifies its offerings with the introduction of ‘Peripherics’ (Paclitaxel Drug coated PTA balloon)
 
SMT forges a strategic partnership with Penumbra.
2020
SMT announces entry in Structural Heart Segment with the acquisition of Vascular Concepts and Vascular Innovations.
2019
Talent Trial gets published in The Lancet journal. The Journal is very well renowned with an impact factor more than 59 [2018]. The Lancet is currently ranked second among 150 journals in the 'General & Internal Medicine' subject category.
2018
The Talent Trial results presented in late-breaking clinical trial session at TCT 2018, San Diego, USA.
Results: The Talent Trial non-inferiority proved there was 61% reduction in clinically driven TLR in per-protocol analysis as published in The Lancet.
Talent Result
2018
SMT launches Supraflex Cruz (Sirolimus Eluting Cobalt Chromium Coronary Stent System), which provides ultimate deliverability through its breakthrough design; making it truly convenient for the Interventional Cardiologists to treat even the most complex cases with ease.
2016
As SMT grows leaps & bounds in a decade, it also attracts the attention of some key investors. SMT receives investment from Samara Capital.
2016
SMT Ireland
SMT launches its operations in Europe by setting up state-of-the-art R&D centre in Galway, Ireland.
2016
SMT glide
SMT further extends its product basket by launching:
  • TetriflexTM (Sirolimus Eluting Cobalt Chromium Coronary Stent System)
  • SMT Glide Diagnostic Catheter
2016
After launching a slew of cutting edge products in India, Talent trial gets initiated in 7 countries with 1435 patients in 23 centres across Europe, benchmarking Supraflex* to Xience.*
2015
SMT launches 3 new products:
  • RenofitTM (Balloon Expandable Cobalt Chromium RENAL and BILIARY Stent System)
  • TetrilimusTM (Everolimus Eluting Cobalt Chromium Coronary Stent System)
  • WilmaTM (PTCA Dilatation Catheter)
2013

Within a year SMT receives yet another CE approval for Supraflex, which brings the company at par with some of the leading stent manufacturers in the world.
2012
SMT receives CE approval for the coronary stents systems Supralimus & Supralimus Core.
Supralimus Logo
Supralimus Core Logo
2005
SMT Receive the CE certification for a DES with a biodegradable polymer on Infinnium.
CE Certification
2001
Received CE Certificate for coronary stents.
Matrix

* Specifications are subject to modification, revision and improvement.
Supraflex is a registered trademark of Sahajanand Medical Technologies or its affiliates. Xience is a trademark or registered trademark of the Abbott Group of Companies.